Skip to main content

Aerie Pharmaceuticals, Inc. (AERI)

NASDAQ: AERI · IEX Real-Time Price · USD
9.65 -0.11 (-1.13%)
Dec 8, 2021 4:00 PM EST - Market closed
Market Cap457.00M
Revenue (ttm)104.15M
Net Income (ttm)-166.48M
Shares Out47.36M
EPS (ttm)-3.61
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,914,091
Open9.92
Previous Close9.76
Day's Range9.26 - 9.93
52-Week Range9.15 - 21.30
Beta0.85
AnalystsBuy
Price Target23.13 (+139.7%)
Earnings DateNov 4, 2021

About AERI

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is al...

IndustryPharmaceuticals
IPO DateOct 25, 2013
CEOVicente Anido
Employees365
Stock ExchangeNASDAQ
Ticker SymbolAERI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for AERI stock is "Buy." The 12-month stock price forecast is 23.13, which is an increase of 139.69% from the latest price.

Price Target
$23.13
(139.69% upside)
Analyst Consensus: Buy

News

Aerie Concludes Exclusive License Agreement With Santen for Rhopressa® and Rocklatan® in Europe and Several Other Reg...

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Aerie and Santen have entered into an exclusive development and commercialization agreement for Rhopress...

2 days ago - Business Wire

Aerie Pharmaceuticals to Participate in Upcoming Investor Conferences

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...

4 weeks ago - Business Wire

Aerie's (AERI) Q3 Earnings Miss Estimates, Revenues Rise Y/Y

Aerie (AERI) incurs wider-than-expected loss in the third quarter of 2021 while sales match expectations.

1 month ago - Zacks Investment Research

Aerie Pharmaceuticals (AERI) Reports Q3 Loss, Tops Revenue Estimates

Aerie (AERI) delivered earnings and revenue surprises of -16.13% and 0.63%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Aerie Pharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today reported financial results for the third quarter ended September 30, 2021 and provid...

1 month ago - Business Wire

Aerie Pharmaceuticals (AERI) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Aerie (AERI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Aerie Pharmaceuticals to Announce Third Quarter 2021 Financial Results and Host Conference Call on Thursday, November...

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, announced today that its third quarter 2021 financial results will be released after the ...

1 month ago - Business Wire

Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Glaucoma Innovation Showcase

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Tom Mitro, President and Chief Operating Officer presented an overvi...

1 month ago - Business Wire

Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Tr...

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company, today reported positive topline results for the Company's Phase 3 clinical trial in Japan ...

1 month ago - Business Wire

Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit Retina Innovation Showcase

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that Casey Kopczynski, Ph.D., Chief Scientific Officer presented an overv...

2 months ago - Business Wire

Aerie Pharmaceuticals Announces Presentation at the 39th Annual Scientific Meeting of the American Society of Retina ...

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that topline results from the AR-1105 (dexamethasone intravitreal implant...

2 months ago - Business Wire

Aerie Pharmaceuticals to Participate in the Cantor Global Healthcare Conference

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...

2 months ago - Business Wire

Aerie Pharmaceuticals, Inc. Announces the Appointment of Interim Executive Chair and Departure of Chairman and CEO

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company, today announced that it is executing its succession plan for its long-serving Chairman an...

2 months ago - Business Wire

Aerie Pharmaceuticals Announces Appointment of Erik Pacyniak, Ph.D., D.A.B.T., as Director, Toxicology and Drug Dispo...

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...

2 months ago - Business Wire

Aerie (AERI) Announces Mixed Data From Dry Eye Disease Study

Aerie Pharmaceuticals (AERI) reports mixed data from the phase IIb study evaluating AR-15512 for treating dry eye disease. Resultantly, the stock declines in after-market trading on Sep 15.

2 months ago - Zacks Investment Research

Aerie Pharmaceuticals Announces Novel Dry Eye Product Candidate AR-15512 (TRPM8 Agonist) Ophthalmic Solution Achieved...

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...

2 months ago - Business Wire

Aerie Pharmaceuticals Announces Appointment of Carolyn McAuliffe, Senior Director, Communications

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...

2 months ago - Business Wire

Aerie (AERI) Down 0.9% Since Last Earnings Report: Can It Rebound?

Aerie (AERI) reported earnings 30 days ago. What's next for the stock?

3 months ago - Zacks Investment Research

Aerie Pharmaceuticals to Participate in the H.C. Wainwright Ophthalmology Conference

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...

3 months ago - Business Wire

Aerie's(AERI) Q2 Loss Wider Than Expected, Revenues Beat

Aerie (AERI) incurs wider-than-expected loss in the second quarter of 2021 but sales beat expectations.

4 months ago - Zacks Investment Research

Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates

Aerie (AERI) delivered earnings and revenue surprises of -3.08% and 2.85%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Aerie Pharmaceuticals Reports Second Quarter 2021 Financial Results and Provides Business Update

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...

4 months ago - Business Wire

Aerie Pharmaceuticals to Announce Second Quarter 2021 Financial Results and Host Conference Call on Wednesday, August...

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...

4 months ago - Business Wire

Aerie Pharmaceuticals Announces Presentation at the Ophthalmology Innovation Summit European Innovation Showcase

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...

4 months ago - Business Wire

Aerie Pharmaceuticals Announces Appointment of Leon J. Atencia, Director of Regulatory Affairs

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...

4 months ago - Business Wire